Braveheart Bio

News

Quartet of biotechs join Nasdaq after stellar IPOs

Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.

News

Apnimed IPO raises $192m, as three other biotechs set terms

Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.

News

Two more biotechs, Attovia and Braveheart, join the IPO line

The steady stream of biotechs aiming to list on the Nasdaq has continued, with Attovia and Braveheart the latest to make their intentions known.

News

Braveheart, AAVantgarde rounds head recent biofinancings

Our latest crop of biotech financings has nine-figure rounds for Braveheart and AAVantgarde, with Azalea Therapeutics and NEOK Bio also raising funds.

Quartet of biotechs join Nasdaq after stellar IPOs

Apnimed IPO raises $192m, as three other biotechs set terms

Two more biotechs, Attovia and Braveheart, join the IPO line

Braveheart, AAVantgarde rounds head recent biofinancings

Merck rare tumour drug Ezmekly backed for NHS use

Discover a new era of healthcare panel engagement: Grounded ...

Braveheart Bio

Editor's Picks